Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

Table 2 Proportion of csDMARD-IR patients reporting each clinically meaningful PRO improvement at month 3

PRO, n (%)	Tofacitinib 5 mg BID + csDMARDs (N = 695)	Placebo + csDMARDs (N = 366)
PtGA
LDA (PtGA VAS score ≤ 20 mm)	216 (31.1)	62 (16.9)
Moderate PtGA improvement (≥ 30% decrease from baseline)^a	421 (60.8)	119 (32.6)
Substantial PtGA improvement (≥ 50% decrease from baseline)^a	301 (43.5)	73 (20.0)
Pain
Mild Pain (VAS score ≤ 20 mm)	246 (35.4)	62 (16.9)
Moderate Pain improvement (≥ 30% decrease from baseline)^a	419 (60.5)	124 (34.0)
Substantial Pain improvement (≥ 50% decrease from baseline)^a	310 (44.8)	70 (19.2)
HAQ-DI
HAQ-DI score ≥ normative value (≤ 0.25)	142 (20.4)	44 (12.0)
HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)^b	463 (66.8)	166 (45.6)
FACIT-F
FACIT-F score ≥ normative value (≥ 43.5)^c	138 (19.9)	46 (12.6)
FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)^d	381 (55.0)	131 (36.1)

Abbreviations: BID twice daily, csDMARD conventional synthetic disease-modifying antirheumatic drug, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, LDA low disease activity, MCID minimum clinically important difference, PRO patient-reported outcome, PtGA Patient Global Assessment of Disease Activity, VAS Visual Analog Scale
^aTofacitinib 5 mg BID + csDMARDs, N = 692; placebo + csDMARDs, N = 365
^bTofacitinib 5 mg BID + csDMARDs, N = 693; placebo + csDMARDs, N = 364
^cTofacitinib 5 mg BID + csDMARDs, N = 694; placebo + csDMARDs, N = 365
^dTofacitinib 5 mg BID + csDMARDs, N = 693; placebo + csDMARDs, N = 363

ISSN: 1478-6362